Dimerix Limited · ASX:DXB
Dimerix — Emergence23 Wholesale Investor Conference 2023
13 slides from Dimerix's conference presentation, Mar 22, 2023
Slide 1: Investor Briefing Notice
For Immediate Release INVESTOR BRIEFING NOTICE For personal use only MELBOURNE, Australia, 22 March 2023: Dimerix Limited (ASX: DXB) a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, is pleased to advise that CEO & Managing Director, Dr Nina Webster, will be prese
Slide 2: About Dimerix
About Dimerix Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complic
Slide 3: FSGS Clinical Study
o : ACTICING @w Dimerix: FSGS CLINICAL STUDY Developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease (ASX:DXB) (ih Wholesale Investor Presentation L) B\ os March 2023
Slide 4: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown, risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different. f
Slide 5: Late stage Phase 3 clinical development asset
Late stage, phase 3 clinical development asset Near term Phase 3 interim analysis, and potential accelerated approval pathway 46. Advanced partnering negotiations with offers received from y ‘S multiple parties for various territories! hee Comprehensive development plan to ensure commercial+ready, p
Slide 6: Significantly de-risked, late-stage development program
Significantly de-risked, late-stage development program mes Strong safety profile! Proven efficacy! Completed toxicology studies? TL MT Completed commercial Clear development Orphan Drug manufacturing scale-up? pathway to market* designations® @w Dimerix 0: 2 1 A 202: 28Nov"9, 3. ASX ‘14Dect5, 21Nov
Slide 7: Targeting orphan disease
Targeting orphan disease Commercially attractive pricing structure (“US$120,000 potential cost per year based on rare kidney treatments’, average US orphan drug price of $84,000/year in 2018) A, \ve ~ Opportunity for accelerated approval on compelling 5 interim data with rapid incorporation into KDI
Slide 8: Orphan disease treatment — case study
Orphan disease treatment — case study Pipeline focus on rare neurodevelopmental disorders pharmaceuticals, Phase 3 study wo NDA submission commence US commercial partner FDA marketing Top line Phase 3 clata approval Chart generated on 14/3/2023 at 10:41 am Market cap : Market cap : Market cap Market
Slide 9: FSGS has large unmet medical need
FSGS has large unmet medical need With no therapies approved for the treatment of FSGS: patients are treated with other medications off-label, including angiotensin receptor blockers * patients likely end up on dialysis and/or kidney transplant Market drive: * current market specifically for FSGS do
Slide 10: DMX-200 — working on inflammatory signalling pathway
DMX-200 — working on inflammatory signalling pathway > A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) New Chemical Entity status, 2 x 120mg capsule daily e Consistently safe and well e 4 clinical studies completed f w
Slide 11: Clinical trial status
O: ACTIGN3 Clinical trial status FSGS CLINICAL STUDY Part1: global study recruiting across “70 sites in 11 countries: * Geographically diverse to meet differing regulatory requirements; Part 2: additional countries and sites will open following A randomised, double-blind, multi-centre, placebo-contr
Slide 12: Late stage Phase 3 clinical development asset
Late stage, phase 3 clinical development asset Near term Phase 3 interim analysis, and potential accelerated approval pathway 46. Advanced partnering negotiations with offers received from y ‘S multiple parties for various territories! hee Comprehensive development plan to ensure commercial+ready, p
Slide 13: Dimerix
Dimerix A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. Well positioned to deliver against strategic plan SCAN ME AS x : DX B 425 Smith St, Fert 508s Victo
Dimerix — Emergence23 Wholesale Investor Conference 2023 on 6ix